Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Millennium Pharmaceuticals, Inc. (MLNM) -- Ignore unavailable to you. Want to Upgrade?

To: Icebrg who wrote (2144)	6/24/2004 1:43:29 PM
From: Icebrg	Read Replies (1) \| Respond to of 3044

Millennium Pharmaceuticals "neutral" Thursday, June 24, 2004 2:41:19 AM ET Robert W. Baird NEW YORK, June 24 (New Ratings) - Analysts at Robert W Baird maintain their "neutral" rating on Millennium Pharmaceuticals Inc (MLNM.NAS). The target price is set to $17. In a research note published yesterday, the analysts mention that the company has licensed its rights to GlaxoSmithKline for the marketing of Integrilin in Europe. The company has also re-acquired its European rights from Schering-Plough, Millennium Pharmaceuticals’ former European partner, the analysts say. Robert W Baird believes that the alignment with GlaxoSmithKline would boost Millennium Pharmaceuticals' European commercial presence.